JLE

Hépato-Gastro & Oncologie Digestive

MENU

Hepatocellular carcinoma: identification of patients at risk and screening Volume 29, issue 9, November 2022

Authors
1 Nantes Université, CHU Nantes, Institut des Maladies de l’Appareil Digestif (IMAD), Service d’hépatogastroentérologie, Inserm CIC 1413, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1
2 L’Hôpital privé du Confluent, Service d’hépato-gastroentérologie, Rezé
3 Clinique Jules Verne, Service d’hépato-gastroentérologie Nantes
4 Clinique Santé Atlantique, Service d’hépato-gastroentérologie, Saint-Herblain
Correspondance : Y. Touchefeu

Hepatocellular carcinoma (HCC) develops in most cases in a cirrhotic liver. HCC screening allows for an earlier diagnosis of HCC, more frequent access to treatments with curative intents, and improved patient survival. In France, biannual abdominal ultrasound screening for HCC is recommended for cirrhotic patients. However, only 20% of patients are diagnosed with HCC in a screening program. In case of patients diagnosed outside a screening programm, it may be either because they have known cirrhosis but are not properly followed, or because they have no known cirrhosis or liver fibrosis. Recognizing patients at risk for chronic liver disease and identifying advanced fibrosis in these patients are areas for optimizing HCC screening.